Despite a correlation with the expression of immune checkpoint genes, when exploring the dataset from Miao et al. (2018) [28], no response in the expression of INVS or its interactome partners NPHP3, DVL1, DVL3, and ANKS6 after treatment with various immune checkpoint inhibitors (pembrolizumab, ipilimumab, nivolumab, and atezolizumab) was observed in ccRCC, urothelial cancer, or melanoma. The gene discussed is DVL1; the disease is nonpapillary renal cell carcinoma.